Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including:

• New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer
• Intravesical therapies such as nadofaragene and N-803
• The role of ctDNA in measurable residual disease detection

Presenters:

Sam S. Chang, MD, MBA
Patricia and Rodes Hart Chair of Urologic Surgery
Chief Surgical Officer
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Matthew D. Galsky, MD
Lillian and Howard Stratton Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Link to full program: 
https://bit.ly/479RgQn

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.